Assessment of the mir-218, mir-146 and mir-222 expression before and after treatment with sodium valperat epileptic patients blood and relationship with polycystic ovary syndrome

Assessment of the mir-218, mir-146 and mir-222 expression before and after treatment with sodium valperat epileptic patients blood and relationship with polycystic ovary syndrome.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190213042701N1

Enrollment

Registered

2019-05-04

Start date

2016-09-20

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Focal epilepsy and partial epilepsy. Condition 2: Polycystic ovarian syndrome. Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group:1- Group (Individuals who are aged between 18 and 40 years old have not taken any contraceptive during their use. who were selected for this study (epilepsy), have h

new-case and have no history of liver and kidney problems, (chemotherapy test: Alanine amino transferase-espartate, amino transferase, more than 3 unit of normal range and failure kidney means had

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: The study was carried out on 30 Iranian WWE at reproductive ages(18-35) who take part in this study are mono-therapy with vlproic acid (VPA) PCOs was defined NIH criteria They have generalize or partial epilepsy

Exclusion criteria

Exclusion criteria: The women with history of diabetes The women with history of kidney disease The women with history of liver disease The women with history of thyroid dysfunction disease Individuals with history of endocrine comorbidity disease Syndromic epilepsy patient and cataminal epilepsy or MTLE has excluded

Design outcomes

Primary

Measure	Time frame
Mir-146 expression increase or decrease proportional to control group and compare increase amount estradiol hormone and AMH. Timepoint: amount of mir-146 in before treatment with Sodium valproate for first time and then amount mir-146 again in patients blood get trapy with Sodium valproate. Method of measurement: realtime-pcr.	—

Secondary

Measure	Time frame
Mir-222 expression increase or decrease proportional to control group and compare increase amount estradiol hormone and AMH. Timepoint: amount of mir-222 in before treatment with Sodium valproate for first time and then amount mir-222 again in patients blood get trapy with Sodium valproate. Method of measurement: realtime-pcr.;Mir-218 expression increase or decrease proportional to control group and compare increase amount estradiol hormone and AMH. Timepoint: amount of mir-218 in before treatment with Sodium valproate for first time and then amount mir-218 again in patients blood get trapy with Sodium valproate. Method of measurement: realtimepcr.	—

Measure

Time frame

Mir-222 expression increase or decrease proportional to control group and compare increase amount estradiol hormone and AMH. Timepoint: amount of mir-222 in before treatment with Sodium valproate for first time and then amount mir-222 again in patients blood get trapy with Sodium valproate. Method of measurement: realtime-pcr.;Mir-218 expression increase or decrease proportional to control group and compare increase amount estradiol hormone and AMH. Timepoint: amount of mir-218 in before treatment with Sodium valproate for first time and then amount mir-218 again in patients blood get trapy with Sodium valproate. Method of measurement: realtimepcr.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahya Rajabi

Iranian academic center for education culture and research

mahya_rajabi@yahoo.com+98 35182470856

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026